Publications by authors named "S Bormioli"
Background: To assess the clinical effectiveness of Tocilizumab (TCZ) in moderate-to-severe hospitalized COVID-19 patients and factors associated with clinical response.
Methods: Five hundred eight inpatients with moderate-to-severe SARS-CoV-2 infection were enrolled. TCZ effect in addition to standard medical therapy was evaluated in terms of death during hospital stay.
Article Synopsis
- Mepolizumab, an anti-IL-5 monoclonal antibody, showed significant benefits for patients with severe eosinophilic asthma, including fewer exacerbations and improved asthma control over a 36-month study.
- The study, involving 51 patients, found that the annual rate of asthma exacerbations dropped significantly from 5.1 to 0.8 events per person per year after starting mepolizumab treatment.
- Patients also experienced a substantial reduction in oral corticosteroid use and a high retention rate of the medication throughout the study, confirming its long-term effectiveness in managing asthma symptoms.
Benralizumab: Resolution of Eosinophilic Pulmonary Vasculitis in a Patient With EGPA.
J Investig Allergol Clin Immunol
December 2021
Background: Asthma, and severe asthma in particular, is often managed within a specialized field with allergists and clinical immunologists playing a leading role. In this respect, the National Scientific Society SIAAIC (Società Italiana di Allergologia, Asma ed Immunologia Clinica), structured in Regional and Inter-Regional sections, interviewed a large number of specialists involved in the management of this respiratory disease.
Methods: A survey entitled "Management of patients with asthma and severe asthma" based on 17 questions was conducted through the SIAAIC newsletter in 2019 thanks to the collaboration between GlaxoSmithKline S.
Background: Immune-related adverse events (irAEs) are inflammatory side effects, which can occur during immune-checkpoint(s) inhibitors (ICIs) therapy. Steroids are the first-line agents to manage irAEs because of their immunosuppressive properties. However, it is still debated whether or when steroids can be administered without abrogating the therapeutic efforts of immunotherapy.
View Article and Find Full Text PDF